GeneDx (WGS) Expected to Announce Earnings on Wednesday

GeneDx (NASDAQ:WGS) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, April 30th. Analysts expect GeneDx to post earnings of $0.11 per share and revenue of $79.90 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million for the quarter, compared to analysts’ expectations of $82.24 million. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Price Performance

WGS opened at $96.89 on Wednesday. The company’s 50-day simple moving average is $94.57 and its two-hundred day simple moving average is $80.67. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The stock has a market capitalization of $2.72 billion, a P/E ratio of -49.43 and a beta of 1.93. GeneDx has a 52-week low of $10.18 and a 52-week high of $115.60.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. TD Cowen increased their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

Insider Activity at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 1,657 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the completion of the sale, the chief executive officer now owns 3,937 shares of the company’s stock, valued at approximately $308,975.76. The trade was a 29.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Kevin Feeley sold 922 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the completion of the sale, the chief financial officer now owns 5,446 shares of the company’s stock, valued at approximately $515,845.12. The trade was a 14.48 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 138,780 shares of company stock worth $12,907,437. 27.30% of the stock is owned by company insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.